AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Physicians recommend that patients with chronic obstructive pulmonary disease (COPD) quit smoking and use steroids, ...

The growing prevalence of COPD among women can be attributed to a combination of biological, environmental, and societal ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Chronic obstructive pulmonary disease (COPD) market Insights: Rising prevalence of COPD due to aging and smoking.

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.